



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Preliminary Final Report 30 June 2021

Sydney, Australia & Auckland, New Zealand, 30 August 2021 – Living Cell Technologies Limited (LCT) today announced the Preliminary Final Report (Appendix 4E) on the financial results for the year ended 30 June 2021. In accordance with Listing Rule 4.3A, the report is attached.

The COVID-19 pandemic continued to affect the business throughout the 12 months to 30 June. During this financial year the company terminated the projects with the University of Auckland and undertook a range of cost-saving measures.

LCT is in ongoing and active discussions with a number of entities around potential new research projects with a view to securing a potential return on shareholders' investments. The company also continues to look for investors to pursue clinical studies of NTCELL in Parkinson's disease.

Financial Results

The loss after income tax from continuing operations has increased from \$(968,469) in the year ended 30 June 2020 to \$(1,460,591) last year.

Revenue and other income decreased from \$553,692 to \$268,184 due mainly to reduced grant income as research and development expenditure reduced in the second half due the termination of the University of Auckland research projects. Research and development expenses also decreased due to this from \$(2,372,801) to \$(1,609,230)

Cash and cash equivalents decreased from \$2,964,874 to \$1,568,928 due to investing into product opportunities while containing costs.

– Ends –

For further information: www.lctglobal.com

At the Company: Bernie Tuch Interim Chief Executive Mobile: +61 411 461 604 btuch@lctglobal.com	Media Contact: Rachael Joel Botica Butler Raudon Partners Mobile: +64 21 403 504 rachaelj@botica.co.nz
---	--

About Living Cell Technologies

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company that has focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT has outlicensed DIABECCELL (alginate coated capsule containing neonatal porcine pancreatic cells) to Diatranz Otsuka Limited to continue the development of a cell therapy for type 1 diabetes in return for a royalty arrangement.

LCT is seeking investors for the next step in the development of NTCELL (alginate coated capsule containing clusters of neonatal porcine choroid plexus cells) after completing phase IIa and IIb clinical studies in Parkinson's disease. In a Phase IIb trial of NTCELL, there was not a statistically significant difference between the groups who received NTCELL and the placebo group at the 26-week study endpoint. However, at 24 months post-implant a clinically relevant effect was observed (<-6.45 points from baseline) in two of the three treatment groups. LCT is now looking to conduct a third clinical trial in a large cohort of recipients seeking to alter the rate of disease progression.

LCT also continues to seek new product project opportunities as well as interactions that leverage its financial assets.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information, visit www.lctglobal.com or follow @lctglobal on Twitter.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.